ICD-10-CM Billable Code

E88.14

HIV-associated lipodystrophy

Clinical Classification Guidelines

Use Additional Code

  • code for adverse effect, if applicable, to identify drug (T37.5X5-)

Code First

  • any human immunodeficiency virus [HIV] disease (B20)

Medical Intelligence & Overview

HIV-associated lipodystrophy is a condition that affects individuals living with HIV. It involves abnormal changes in body fat distribution, which can impact physical appearance and overall health. This condition is often linked to long-term antiretroviral therapy (ART), a critical component in managing HIV. Recognizing the signs and understanding the underlying causes can help in managing the physical and emotional effects of this condition.

Causes & Symptoms

Clinical Causes: Prolonged use of antiretroviral medications, especially certain classes such as protease inhibitors and nucleoside reverse transcriptase inhibitors Alterations in fat metabolism and storage due to HIV infection itself Genetic predispositions influencing fat distribution and metabolism Lifestyle factors, including diet, exercise, and smoking habits Metabolic changes caused by aging or other health conditions

Key Symptoms: Increase in fat deposits in specific areas such as the abdomen, neck, or breasts Fat loss in areas like the face, arms, legs, and buttocks, leading to a gaunt appearance Development of a buffalo hump (fat accumulation at the back of the neck) Thinning of the skin and potential development of stretch marks Altered body shape that may cause psychological distress or self-esteem issues Possible metabolic disturbances such as insulin resistance or dyslipidemia

Diagnostic & Treatment

Diagnosis Path: Diagnosis of HIV-associated lipodystrophy involves a thorough medical history and physical examination. Healthcare providers may assess changes in body fat distribution over time. Additional tests such as imaging studies (e.g., MRI or DEXA scans), blood tests to evaluate lipid profiles, blood sugar levels, and metabolic markers may be conducted to support the diagnosis. Since the condition is closely linked to antiretroviral therapy, reviewing medication history is also vital.

Treatment Protocols: While there's no cure for lipodystrophy, several approaches aim to manage its physical effects and improve quality of life. Strategies include: - Adjusting or switching antiretroviral medications under medical supervision to reduce progression - Implementing lifestyle modifications like balanced diet and regular exercise to promote healthy body composition - Managing metabolic abnormalities with medications prescribed by healthcare providers - Counseling and psychological support to address self-esteem and emotional well-being - Use of plastic or cosmetic procedures in some cases to improve appearance Collaborative care involving healthcare providers, dietitians, and mental health professionals can help tailor approaches suited to individual needs.

Reimbursement claims with a date of service on or after October 1, 2015 require the use of ICD-10-CM codes.

Clinical Advice & FAQs

Billing Guidance

Is E88.14 a billable ICD-10 code?
Yes, E88.14 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.

Documentation

How do I report E88.14?
Clinical documentation must specify the nature of HIV-associated lipodystrophy and any associated comorbidities for accurate reporting.

Cite this Clinical Reference